Q1 2025 Management View CEO Olivier Loeillot highlighted strong Q1 organic revenue growth, reporting an 11% organic increase, with non-COVID growth reaching 14%. Proteins showed the strongest ...

This is the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and ...

Kennedy has focused his healthcare crusade on his contention that American healthcare prioritizes treating chronic illnesses ...

The Trump administration's effort to impose new requirements on Novavax's COVID-19 vaccine -- the nation's only traditional ...

Among other things, Makary breaks some news here by stating, for the first time, that there will be no significant ...

While Vaxart can proceed with its study, fellow COVID-19 vaccine developers GeoVax and Novavax continue to be hamstrung by ...

NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the “Company”), and a leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine ...

President Trump’s first 100 days has roiled health and science as part of the administration’s plan to reshape the federal ...

FDA vaccine oversight is shifting, with increased scrutiny and mixed messaging sparking concerns among health experts.

The President Donald Trump administration's request for Novavax Inc. to conduct new clinical trials for its COVID-19 vaccine has created uncertainty across the vaccine industry, potentially affecting ...

In a recent interview, FDA Commissioner Marty Makary said there “should be nothing political about the FDA.” Recent actions ...

Novavax is working with the FDA to meet additional requirements and hopes to secure full approval as soon as possible.